Inflammatory Breast Cancer

Seminars in Radiation Oncology

Volumn 19, Issue 4, 2009, Pages 256-265

  Woodward, Wendy A ^a   Cristofanilli, Massimo ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CAPECITABINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; LAPATINIB; MUCIN 1; MYC PROTEIN; PACLITAXEL; PROGESTERONE RECEPTOR; PROTEIN P53; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; TRASTUZUMAB; UVOMORULIN;

BODY MASS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CANCER INVASION; CANCER RECURRENCE; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DOSIMETRY; ETHNIC DIFFERENCE; HUMAN; INFLAMMATORY BREAST CANCER; LYMPH NODE METASTASIS; LYMPHOCYTIC INFILTRATION; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; OVERALL SURVIVAL; PREMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; REVIEW; RISK FACTOR; SURVIVAL RATE; TREATMENT FAILURE; TUMOR VASCULARIZATION;

BREAST; BREAST NEOPLASMS; ERYTHEMA; FEMALE; HUMANS; INFLAMMATION; SKIN;

EID: 69249222734     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semradonc.2009.05.008     Document Type: Review

References (106)

1. Anderson W.F., Schairer C., Chen B.E., et al. Epidemiology of inflammatory breast cancer (IBC). Breast Dis 22 (2005) 9-23
2. Bell C. A System of Operative Surgery vol 2 (1814), Hale and Homser, Hartford, CT
3. Lee B., and Tannenbaum N. Inflammatory carcinoma of the breast: A report of twenty-eight cases from the breast clinic of Memorial Hospital. Surg Gynecol Obstet 39 (1924) 580
4. Greene F.L., Page D.L., Fritz A., et al. Breast. AJCC Cancer Staging Manual (2002), Springer-Verlag, New York, NY 255-281
5. Denoix P. Treatment of malignant breast cancer. Recent Results in Cancer Research (1970), Springer-Verlag, Berlin 92-94
6. Mourali N., Muenz L.R., Tabbane F., et al. Epidemiologic features of rapidly progressing breast cancer in Tunisia. Cancer 46 (1980) 2741-2746
7. Mourali N., Tabbane F., Muenz L.R., et al. Ten-year results utilizing chemotherapy as primary treatment in nonmetastatic, rapidly progressing breast cancer. Cancer Invest 11 (1993) 363-370
8. Hance K.W., Anderson W.F., Devesa S.S., et al. Trends in inflammatory breast carcinoma incidence and survival: The surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst 97 (2005) 966-975
9. Levine P.H., Steinhorn S.C., Ries L.G., et al. Inflammatory breast cancer: The experience of the surveillance, epidemiology, and end results (SEER) program. J Natl Cancer Inst 74 (1985) 291-297
10. Chang S., Parker S.L., Pham T., et al. Inflammatory breast carcinoma incidence and survival: The surveillance, epidemiology, and end results program of the National Cancer Institute, 1975-1992. Cancer 82 (1998) 2366-2372
11. Wingo P.A., Jamison P.M., Young J.L., et al. Population-based statistics for women diagnosed with inflammatory breast cancer (United States). Cancer Causes Control 15 (2004) 321-328
12. American Cancer Society. Cancer Facts and Figures (2007), American Cancer Society, Atlanta
13. Chang S., Buzdar A.U., and Hursting S.D. Inflammatory breast cancer and body mass index. J Clin Oncol 16 (1998) 3731-3735
14. Levine P.H. Factors for the development of aggressive inflammatory and non-inflammatory breast cancer. Breast Cancer Res Treat suppl 1 (2004) S91
15. Swanson C.A., Brinton L.A., Taylor P.R., et al. Body size and breast cancer risk assessed in women participating in te breast Cancer Detection Demonstration project. Am J Epidemiol 130 (1989) 1133-1141
16. Bonnier P., Charpin C., Lejeune C., et al. Inflammatory carcinomas of the breast: A clinical, pathological, or a clinical and pathological definition?. Int J Cancer 62 (1995) 382-385
17. Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science 251 (1991) 1451-1455
18. Kleer C.G., van Golen K.L., Braun T., et al. Persistent E-cadherin expression in inflammatory breast cancer. Mod Pathol 14 (2001) 458-464
19. Gamallo C., Palacios J., Suarez A., et al. Correlation of E-cadherin expression with differentiation grade and histological type in breast carcinoma. Am J Pathol 142 (1993) 987-993
20. Oka H., Shiozaki H., Kobayashi K., et al. Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis. Cancer Res 53 (1993) 1696-1701
21. Bukholm I.K., Nesland J.M., Karesen R., et al. E-cadherin and alpha-, beta-, and gamma-catenin protein expression in relation to metastasis in human breast carcinoma. J Pathol 185 (1998) 262-266
22. Hunt N.C., Douglas-Jones A.G., Jasani B., et al. Loss of E-cadherin expression associated with lymph node metastases in small breast carcinomas. Virchows Arch 430 (1997) 285-289
23. Siitonen S.M., Kononen J.T., Helin H.J., et al. Reduced E-cadherin expression is associated with invasiveness and unfavorable prognosis in breast cancer. Am J Clin Pathol 105 (1996) 394-402
24. Heimann R., Lan F., McBride R., et al. Separating favorable from unfavorable prognostic markers in breast cancer: The role of E-cadherin. Cancer Res 60 (2000) 298-304
25. Colpaert C.G., Vermeulen P.B., Benoy I., et al. Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression. Br J Cancer 88 (2003) 718-725
26. Tomlinson J.S., Alpaugh M.L., and Barsky S.H. An intact overexpressed E-cadherin/alpha, beta-catenin axis characterizes the lymphovascular emboli of inflammatory breast carcinoma. Cancer Res 61 (2001) 5231-5241
27. Alpaugh M.L., Tomlinson J.S., Kasraeian S., et al. Cooperative role of E-cadherin and sialyl-Lewis X/A-deficient MUC1 in the passive dissemination of tumor emboli in inflammatory breast carcinoma. Oncogene 21 (2002) 3631-3643
28. Alpaugh M.L., Tomlinson J.S., Ye Y., et al. Relationship of sialyl-Lewis(x/a) underexpression and E-cadherin overexpression in the lymphovascular embolus of inflammatory breast carcinoma. Am J Pathol 161 (2002) 619-628
29. Charafe-Jauffret E., Tarpin C., Bardou V.J., et al. Immunophenotypic analysis of inflammatory breast cancers: Identification of an "inflammatory signature". J Pathol 202 (2004) 265-273
30. McCarthy N.J., Yang X., Linnoila I.R., et al. Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer. Clin Cancer Res 8 (2002) 3857-3862
31. Paradiso A., Tommasi S., Brandi M., et al. Cell kinetics and hormonal receptor status in inflammatory breast carcinoma. Comparison with locally advanced disease. Cancer 64 (1989) 1922-1927
32. Harvey H.A., Lipton A., Lawrence B.V., et al. Estrogen receptor status in inflammatory breast carcinoma. J Surg Oncol 21 (1982) 42-44
33. Nguyen D.M., Sam K., Tsimelzon A., et al. Molecular heterogeneity of inflammatory breast cancer: A hyperproliferative phenotype. Clin Cancer Res 12 (2006) 5047-5054
34. Jaiyesimi I.A., Buzdar A.U., and Hortobagyi G. Inflammatory breast cancer: A review. J Clin Oncol 10 (1992) 1014-1024
35. Van den Eynden G.G., Van der Auwera I., Van Laere S., et al. Validation of a tissue microarray to study differential protein expression in inflammatory and non-inflammatory breast cancer. Breast Cancer Res Treat 85 (2004) 13-22
36. Aziz S.A., Pervez S., Khan S., et al. Case control study of prognostic markers and disease outcome in inflammatory carcinoma breast: A unique clinical experience. Breast J 7 (2001) 398-404
37. Riou G., Le M.G., Travagli J.P., et al. Poor prognosis of p53 gene mutation and nuclear overexpression of p53 protein in inflammatory breast carcinoma. J Natl Cancer Inst 85 (1993) 1765-1767
38. Turpin E., Bieche I., Bertheau P., et al. Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer. Oncogene 21 (2002) 7593-7597
39. Guerin M., Gabillot M., Mathieu M.C., et al. Structure and expression of c-erbB-2 and EGF receptor genes in inflammatory and non-inflammatory breast cancer: Prognostic significance. Int J Cancer 43 (1989) 201-208
40. Guerin M., Sheng Z.M., Andrieu N., et al. Strong association between c-myb and oestrogen-receptor expression in human breast cancer. Oncogene 5 (1990) 131-135
41. Parton M., Dowsett M., Ashley S., et al. High incidence of Her-2 positivity in inflammatory breast cancer. Breast 13 (2004) 97-103
42. Charpin C., Bonnier P., Khouzami A., et al. Inflammatory breast carcinoma: An immunohistochemical study using monoclonal anti-pHER-2/neu, pS2, cathepsin, ER and PR. Anticancer Res 12 (1992) 591-597
43. Sawaki M., Ito Y., Akiyama F., et al. High prevalence of Her-2/neu and p53 overexpression in inflammatory breast cancer. Breast Cancer 13 (2006) 172-178
44. Foekens J.A., Rio M.C., Seguin P., et al. Prediction of relapse and survival in breast cancer patients by pS2 protein status. Cancer Res 50 (1990) 3832-3837
45. Prost S., Le M.G., Douc-Rasy S., et al. Association of c-erbB2-gene amplification with poor prognosis in non-inflammatory breast carcinomas but not in carcinomas of the inflammatory type. Int J Cancer 58 (1994) 763-768
46. Gonzalez-Angulo A.M., Sneige N., Buzdar A.U., et al. p53 expression as a prognostic marker in inflammatory breast cancer. Clin Cancer Res 10 (2004) 6215-6221
47. Faille A., De Cremoux P., Extra J.M., et al. p53 mutations and overexpression in locally advanced breast cancers. Br J Cancer 69 (1994) 1145-1150
48. Resetkova E., Gonzalez-Angulo A.M., Sneige N., et al. Prognostic value of P53, MDM-2, and MUC-1 for patients with inflammatory breast carcinoma. Cancer 101 (2004) 913-917
49. Aas T., Borresen A.L., Geisler S., et al. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 2 (1996) 811-814
50. Kandioler-Eckersberger D., Ludwig C., Rudas M., et al. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res 6 (2000) 50-56
51. van Golen K.L., Davies S., Wu Z.F., et al. A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. Clin Cancer Res 5 (1999) 2511-2519
52. van Golen K.L., Wu Z.F., Qiao X.T., et al. RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res 60 (2000) 5832-5838
53. Kleer C.G., van Golen K.L., Zhang Y., et al. Characterization of RhoC expression in benign and malignant breast disease: A potential new marker for small breast carcinomas with metastatic ability. Am J Pathol 160 (2002) 579-584
54. Kleer C.G., Griffith K.A., Sabel M.S., et al. RhoC-GTPase is a novel tissue biomarker associated with biologically aggressive carcinomas of the breast. Breast Cancer Res Treat 93 (2005) 101-110
55. Van Laere S., Van der Auwera I., Van den Eynden G.G., et al. Distinct molecular signature of inflammatory breast cancer by cDNA microarray analysis. Breast Cancer Res Treat 93 (2005) 237-246
56. Van Laere S.J., Van der Auwera I., Van den Eynden G.G., et al. Nuclear factor-kappaB signature of inflammatory breast cancer by cDNA microarray validated by quantitative real-time reverse transcription-PCR, immunohistochemistry, and nuclear factor-kappaB DNA-binding. Clin Cancer Res 12 (2006) 3249-3256
57. Bozzetti F., Saccozzi R., Lena M.D., et al. Inflammatory cancer of the breast: Analysis of 114 cases. J Surg Oncol 18 (1981) 355-361
58. Barker J.L., Nelson A.J., and Montague E.D. Inflammatory carcinoma of the breast. Radiology 121 (1976) 173-176
59. Zucali R., Uslenghi C., Kenda R., et al. Natural history and survival of inoperable breast cancer treated with radiotherapy and radiotherapy followed by radical mastectomy. Cancer 37 (1976) 1422-1431
60. Thames Jr. H.D., Peters L.J., Withers H.R., et al. Accelerated fractionation vs hyperfractionation: Rationales for several treatments per day. Int J Radiat Oncol Biol Phys 9 (1983) 127-138
61. Barker J.L., Montague E.D., and Peters L.J. Clinical experience with irradiation of inflammatory carcinoma of the breast with and without elective chemotherapy. Cancer 45 (1980) 625-629
62. Thoms Jr. W.W., McNeese M.D., Fletcher G.H., et al. Multimodal treatment for inflammatory breast cancer. Int J Radiat Oncol Biol Phys 17 (1989) 739-745
63. Ueno N.T., Buzdar A.U., Singletary S.E., et al. Combined modality treatment of inflammatory breast carcinoma: Twenty years of experience at M. D. Anderson center. Cancer Chemother Pharmacol 40 (1997) 321-329
64. Blumenschein G., Montague E.D., Eckles N.E., et al. Sequential combined modality therapy for inflammatory breast cancer. Breast 2 (1976) 16-20
65. Koh E.H., Buzdar A.U., Ames F.C., et al. Inflammatory carcinoma of the breast: Results of a combined-modality approach-M. D. Anderson Cancer Center experience. Cancer Chemother Pharmacol 27 (1990) 94-100
66. Singletary S.E., Ames F.C., and Buzdar A.U. Management of inflammatory breast cancer. World J Surg 18 (1994) 87-92
67. Buzdar A.U., Singeltary S.E., Booser D.J., et al. Combined modality treatment of stage III and inflammatory breast cancer. M. D. Anderson Cancer Center experience. Surg Oncol Clin North Am 4 (1995) 715-734
68. Baldini E., Gardin G., Evangelista G., et al. Long-term results of combined-modality therapy for inflammatory breast cancer. Clin Breast Cancer 5 (2004) 358-363
69. Kuerer H.M., Newman L.A., Smith T.L., et al. Clinical course of breast cancer patients with complete pathological primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17 (1999) 460-469
70. Hennessy B.T., Gonzalez-Angulo A.M., Hortobagyi G.N., et al. Disease-free and overall survival after pathological complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy. Cancer 106 (2006) 1000-1006
71. Cristofanilli M., Buzdar A.U., Sneige N., et al. Paclitaxel in the mulitmodality treatment for inflammatory breast carcinoma. Cancer 92 (2001) 1775-1782
72. Cristofanilli M., Gonzalez-Angulo A.M., Buzdar A.U., et al. Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: The M. D. Anderson Cancer Center experience. Clin Breast Cancer 4 (2004) 415-419
73. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353 (2005) 1659-1684
74. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353 (2005) 1673-1684
75. Slamon D.J., Leyland-Jones B., Shak S., et al. Human breast cancer: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2. N Engl J Med 344 (2001) 783-792
76. Buzdar A.U., Ibrahim N.K., Francis D., et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth receptor 2-positive operable breast cancer. J Clin Oncol 23 (2005) 3676-3685
77. Dawood S., Gonzalez-Angulo A.M., Peintinger F., et al. Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: A retrospective review of the M. D. Anderson experience. Cancer 110 (2007) 1195-1200
78. Hurley J., Doliny P., Reis I., et al. Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor: Receptor 2postive locally advanced breast cancer. J Clin Oncol 24 (2006) 1831-1838
79. Van Pelt A.E., Mohsin S., Elledge R.M., et al. Neoadjuvant trastuzumab and docetaxel in breast cancer: Preliminary results. Clin Breast Cancer 4 (2003) 348-353
80. Limentani S.A., Brufsky A.M., Erban J.K., et al. phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressing locally advanced breast cancer. J Clin Oncol 25 (2007) 1232-1238
81. Burstein H.J., Harris L.N., Gelman R., et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: A pilot study. J Clin Oncol 21 (2003) 46-53
82. Xia W., Mullin R.J., Keith B.R., et al. Anti-tumor activity of GW572016: A dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream ERK1/2 and AKT pathways. Oncogene 21 (2002) 6255-6263
83. Ha III B., Hurwitz H.I., Dees E.C., et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 23 (2005) 5305-5313
84. Spector N.L., Blackwell K., Hurley J., et al. EGF103009, a phase II trial of lapatinib monotherapy in patients with relapsed/refractory inflammatory breast cancer (IBC): Clinical activity and biologic predictors of response. J Clin Oncol 24 suppl (2006) 502
85. Cristofanilli M., Boussen H., Baselga J., et al. A phase II combination study of lapatinib and paclitaxel as a neoadjuvant therapy in patients with newly diagnosed inflammatory breast cancer (IBC). Breast Cancer Res Treat 55 (2006) 58 (abstr 1)
86. Arthur D.W., Schmidt-Ullrich R.K., Friedman R.G., et al. Accelerated superfractionated radiotherapy for inflammatory breast carcinoma: Complete response predicts outcome and allows for breast conservation. Int J Radiat Oncol Biol Phys 44 (1999) 289-296
87. de Boer R.H., Allum W.H., Ebbs S.R., et al. Multimodality therapy in inflammatory breast cancer: Is there a place for surgery?. Ann Oncol 11 (2000) 1147-1153
88. Swain S.M., Sorace R.A., Bagley C.S., et al. Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonrnetastatic breast cancer. Cancer Res 47 (1987) 3889-3894
89. Hortobagyi G., Singletary S.E., and Strom E.A. Treatment of locally advanced and inflammatory breast cancer. In: Harris J.R., Lippman M.E., and Morrow M. (Eds). Treatment of Locally Advanced and Inflammatory Breast Cancer (2000), Lippincott, Williams Sc Wis, Philadelphia, PA 645-660
90. Vlastos G., Fomage B.D., Mirza N.W., et al. The correlation of axillary ultrasonography with histologic breast cancer downstaging after induction chemotherapy. Am J Surg 179 (2000) 446-452
91. Fields J.N., Perez C.A., Kuske R.R., et al. Inflammatory carcinoma of the breast: Treatment results on 107 patients. Int J Radiat Oncol Biol Phys 17 (1989) 149-155
92. Fleming R.Y.D., Asmar L., Buzdar A.U., et al. Effectiveness of mastectomy by response to induction chemotherapy for control in inflammatory breast carcinoma. Ann Surg Oncol 4 (1997) 452-461
93. Curcio L.D., Rupp E., Williams W.L., et al. Beyond palliative mastectomy in inflammatory breast cancer-a reassessment of margin status. Ann Surg Oncol 6 (1999) 249-254
94. Liao Z., Strom E.A., Buzdar A.U., et al. Locoregional irradiation for inflammatory breast cancer: Effectiveness of dose escalation in decreasing recurrence. Int J Radiat Oncol Biol Phys 47 (2000) 1191-1200
95. Panades M., Olivotto I.A., Speers C.H., et al. Evolving treatment strategies for inflammatory breast cancer: A population-based survival analysis. J Clin Oncol 23 (2005) 1941-1950
96. Maloisel F., Dufour P., Bergerat J.P., et al. Results of initial doxorubicin, 5-fluorouracil, and cyclophosphamide combination chemotherapy for inflammatory carcinoma of the breast. Cancer 65 (1990) 851-855
97. Harris E.E., Schultz D., Bertsch H., et al. Ten-year outcome after combined modality therapy for inflammatory breast cancer. Int J Radiat Oncol Biol Phys 55 (2003) 1200-1208
98. Liauw S.L., Benda R.K., Morris C.G., et al. Inflammatory breast carcinoma: Outcomes with trimodality therapy for nonmetastatic disease. Cancer 100 (2004) 920-928
99. Chu A.M., Cope O., Russo R., et al. Treatment of early stage breast cancer by limited surgery and radical irradiation. Int J Radiat Oncol Biol Phys 6 (1980) 25-30
100. Pisansky T.M., Schaid D.J., Loprinzi C.L., et al. Inflammatory breast cancer: Integration of irradiation, surgery, and chemotherapy. Am J Clin Oncol 15 (1992) 376-387
101. Eifel P.J. Chemoradiotherapy in the treatment of cervical cancer. Semin Radiat Oncol 16 (2006) 177-185
102. Cox J.D. Chemoradiation for malignant epithelial tumors. Cancer Radiother 2 (1998) 7-11
103. Ethier S.P. Human breast cancer cell lines as models of growth regulation and disease progression. J Mammary Gland Biol Neoplasia 1 (1996) 111-121
104. Alpaugh M.L., Tomlinson J.S., Shao Z.M., et al. A novel human xenograft model of inflammatory breast cancer. Cancer Res 59 (1999) 5079-5084
105. Shirakawa K., Tsuda H., Heike Y., et al. Absence of endothelial cells, central necrosis, and fibrosis are associated with aggressive inflammatory breast cancer. Cancer Res 61 (2001) 445-451
106. Kleer C.G., Zhang Y., Pan Q., et al. WISP3 is a novel tumor suppressor gene of inflammatory breast cancer. Oncogene 21 (2002) 3172-3180